Huaiyuan Guo1, Haijun Ma, Jinliang Wang. 1. Department of Gastroenterology, First Affiliated Hospital to Science and Technology University of Henan, Luoyang, Henan, China.
Abstract
GOALS: To compare the treatment effect of proton pump inhibitor (PPI) therapy and placebo for patients with laryngopharyngeal reflux (LPR). STUDY: PubMed, Cochrane Library, and EMBASE were searched from the date of conception to August 2014. Randomized controlled clinical trials (RCTs) were included in this meta-analysis if they compared the treatment response of PPI therapy and placebo among patients with LPR. The risk difference, the standard mean difference (SMD), and their corresponding 95% confidence intervals (CIs) were calculated for the endpoints evaluated. RESULTS: Fourteen eligible RCTs with 771 participants were identified and analyzed in this meta-analysis. By pooling all eligible data, we found that patients treated with PPI therapy had a significantly higher response rate than those who received placebo (risk difference=0.15; 95% CI, 0.01-0.30). Compared with placebo, PPI therapy could also improve the total reflux symptom index significantly (SMD=1.65; 95% CI, 0.15-3.14), but results of the reflux symptom index varied for specific symptoms. However, PPI therapy did not show any advantage over placebo in the improvement of the reflux finding score (SMD=0.62; 95% CI, -0.96-2.19). CONCLUSIONS: In this meta-analysis of 14 eligible RCTs, we found that in patients with LPR, PPI therapy could improve reflux symptoms significantly compared with placebo.
GOALS: To compare the treatment effect of proton pump inhibitor (PPI) therapy and placebo for patients with laryngopharyngeal reflux (LPR). STUDY: PubMed, Cochrane Library, and EMBASE were searched from the date of conception to August 2014. Randomized controlled clinical trials (RCTs) were included in this meta-analysis if they compared the treatment response of PPI therapy and placebo among patients with LPR. The risk difference, the standard mean difference (SMD), and their corresponding 95% confidence intervals (CIs) were calculated for the endpoints evaluated. RESULTS: Fourteen eligible RCTs with 771 participants were identified and analyzed in this meta-analysis. By pooling all eligible data, we found that patients treated with PPI therapy had a significantly higher response rate than those who received placebo (risk difference=0.15; 95% CI, 0.01-0.30). Compared with placebo, PPI therapy could also improve the total reflux symptom index significantly (SMD=1.65; 95% CI, 0.15-3.14), but results of the reflux symptom index varied for specific symptoms. However, PPI therapy did not show any advantage over placebo in the improvement of the reflux finding score (SMD=0.62; 95% CI, -0.96-2.19). CONCLUSIONS: In this meta-analysis of 14 eligible RCTs, we found that in patients with LPR, PPI therapy could improve reflux symptoms significantly compared with placebo.
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864
Authors: Afrin N Kamal; Shumon I Dhar; Thomas L Carroll; Lee M Akst; Jonathan M Bock; John O Clarke; Jerome R Lechien; Jacqueline Allen; Peter C Belafsky; Joel H Blumin; Walter W Chan; Ronnie Fass; P Marco Fisichella; Michael Marohn; Ashli K O'Rourke; Gregory Postma; Edoardo V Savarino; Michael F Vaezi Journal: Dig Dis Sci Date: 2022-08-22 Impact factor: 3.487
Authors: C Prakash Gyawali; Dustin A Carlson; Joan W Chen; Amit Patel; Robert J Wong; Rena H Yadlapati Journal: Am J Gastroenterol Date: 2020-09 Impact factor: 12.045
Authors: Jérôme R Lechien; Camille Finck; Pedro Costa de Araujo; Kathy Huet; Véronique Delvaux; Myriam Piccaluga; Bernard Harmegnies; Sven Saussez Journal: Eur Arch Otorhinolaryngol Date: 2016-03-23 Impact factor: 2.503
Authors: Rena Yadlapati; Alexander M Kaizer; Daniel R Sikavi; Madeline Greytak; Jennifer X Cai; Thomas L Carroll; Samir Gupta; Sachin Wani; Paul Menard-Katcher; Tsung-Chin Wu; Philip Weissbrod; Andrew M Vahabzadeh-Hagh; John E Pandolfino; Walter W Chan Journal: Clin Gastroenterol Hepatol Date: 2021-05-20 Impact factor: 11.382